Change of Adviser

Advanced Medical Solutions Grp PLC
15 August 2007



For immediate release                                             15 August 2007



                      Advanced Medical Solutions Group plc
                            ('AMS' or 'the Company')


                               Change of Adviser

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global
medical technology company, states that following completion of the acquisition
of Bridgewell Group Plc by Landsbanki Islands hf, the Company is pleased to
announce the appointment of Landsbanki Securities (UK) Limited as Nominated
Adviser and Broker with immediate effect.




For further information, please contact:

Advanced Medical Solutions Group plc                       [phone]
Don Evans, Chief Executive Officer
Mary Tavener, Group Finance Director
www.admedsol.com

Landsbanki Securities (UK) Ltd                            [phone]
Shaun Dobson, Managing Director

Buchanan Communications                                   [phone]
Mark Court/Mary-Jane Johnson




Notes to Editors:

Advanced Medical Solutions is a UK based company developing and providing
leading edge technology to the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, the Company is focused on the design,
development, manufacture and sale of advanced woundcare dressings and products
for closing wounds and sealing tissue.

AMS provides a full range of advanced woundcare products for sale in hospital,
nursing home and community care markets.  The main indications are for chronic
wounds such as ulcers and pressure sores.  These products pioneer the concept of
moist wound healing to allow wounds to heal faster and with less pain and
scarring if they remain moist.  They protect the wound, deal with tissue fluids
and provide an optimal environment for healing to occur.   AMS' resources ensure
a unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move a product from design and development through to production and delivery
ready for distribution into customer markets.

The acquisition of MedLogic in 2002 has brought AMS products based upon
cyanoacrylate adhesive technology which allow the closure of wounds following
trauma or surgical incisions, or seal skin to protect against breakdown or wound
infection.  These products address the emerging tissue adhesives and sealants
segment of the wound closure market.

AMS' technology and products currently serve the majority of the key global
markets and strategic partners.


                      This information is provided by RNS
            The company news service from the London Stock Exchange